A retrospective cohort study on the potential link between dolutegravir-based anti-retroviral therapy and weight gain compared to efavirenz-based anti-retroviral therapy in a tertiary care center in Jabalpur, Madhya Pradesh

Amal C Anil; Sanjay Gedam; Gargi Sethi; Namita Parashar; Namita Barmaiya; Aryasree L; Shivank Sethi

doi:10.5455/njppp.2024.14.05215202429052024

2024, Vol: 14, Issue: 10

14 / 10Current Issue Online First Archive Aims and Scope Abstracting & Indexing Most Accessed Articles Most Downloaded Articles Most Cited Articles

Required files to be uploaded

NJPPP Manuscript Submission Form

« Previous Article

Original Research
Online Published: 11 Jun 2024

Natl J Physiol Pharm Pharmacol. 2024; 14(7): 1454-1458

doi: 10.5455/njppp.2024.14.05215202429052024

A retrospective cohort study on the potential link between dolutegravir-based anti-retroviral therapy and weight gain compared to efavirenz-based anti-retroviral therapy in a tertiary care center in Jabalpur, Madhya Pradesh

Amal C Anil, Sanjay Gedam, Gargi Sethi, Namita Parashar, Namita Barmaiya, Aryasree L, Shivank Sethi.

Abstract
Background: Anti-retroviral therapies (ARTs) for human immunodeficiency virus (HIV) such as dolutegravir (DTG) and efavirenz have been associated with weight gain. Comparing the weight trajectories of the tenofovir/lamivudine/dolutegravir (TLD) and tenofovir/lamivudine/efavirenz (TLE) regimens can give insights into their differential metabolic impact.

Aims and Objectives: The aim of the study was to analyze and compare weight changes in HIV patients on TLE versus TLD regimens over 6 months at a tertiary health center in Jabalpur.

Materials and Methods: This was a retrospective cohort study of 200 HIV patients (100 each on TLE and TLD regimens) from January 2018 to December 2022. Weight change over three prescription time points was recorded. Patients included if >20 years old, on ART >4 weeks, and adherent. Patients excluded if pregnant, comorbidities present, or on ART <4 weeks.

Results: The mean weight increased from 53.86 kg to 54.83 kg (0.97 kg gain) in the TLE group versus 53.79 kg to 58.34 kg (4.55 kg gain) in the TLD group over 6 months. About 53% of TLD patients had a >5% weight gain versus 33% of TLE patients. Analysis of variance showed no significant difference in TLE weight over time (P = 0.864) but a significant TLD weight gain (P = 0.034).

Conclusion: HIV patients on DTG-containing TLD regimen demonstrated a substantial weight gain, whereas TLE regimen patients saw insignificant change. Over half of the TLD patients experienced a concerning >5% weight increase indicating an unfavorable metabolic impact. Health-care providers need awareness of weight gain linked to these HIV drugs to optimize treatment regimens.

Key words: Human Immunodeficiency Virus, Anti-retroviral Therapy, Dolutegravir, Efavirenz, Tenofovir/Lamivudine/Dolutegravir, Tenofovir/Lamivudine/Efavirenz, Weight Gain

	ARTICLE TOOLS
	Abstract
	PDF Fulltext
	How to cite this article
	Citation Tools
	Related Records
	Articles by Amal C Anil Articles by Sanjay Gedam Articles by Gargi Sethi Articles by Namita Parashar Articles by Namita Barmaiya Articles by Aryasree L Articles by Shivank Sethi
	on Google
	on Google Scholar

How to Cite this Article

Pubmed Style

Anil AC, Gedam S, Sethi G, Parashar N, Barmaiya N, L A, Sethi S. A retrospective cohort study on the potential link between dolutegravir-based anti-retroviral therapy and weight gain compared to efavirenz-based anti-retroviral therapy in a tertiary care center in Jabalpur, Madhya Pradesh. Natl J Physiol Pharm Pharmacol. 2024; 14(7): 1454-1458. doi:10.5455/njppp.2024.14.05215202429052024

Web Style

Anil AC, Gedam S, Sethi G, Parashar N, Barmaiya N, L A, Sethi S. A retrospective cohort study on the potential link between dolutegravir-based anti-retroviral therapy and weight gain compared to efavirenz-based anti-retroviral therapy in a tertiary care center in Jabalpur, Madhya Pradesh. https://www.njppp.com/?mno=201702 [Access: November 02, 2024]. doi:10.5455/njppp.2024.14.05215202429052024

AMA (American Medical Association) Style

Anil AC, Gedam S, Sethi G, Parashar N, Barmaiya N, L A, Sethi S. A retrospective cohort study on the potential link between dolutegravir-based anti-retroviral therapy and weight gain compared to efavirenz-based anti-retroviral therapy in a tertiary care center in Jabalpur, Madhya Pradesh. Natl J Physiol Pharm Pharmacol. 2024; 14(7): 1454-1458. doi:10.5455/njppp.2024.14.05215202429052024

Vancouver/ICMJE Style

Anil AC, Gedam S, Sethi G, Parashar N, Barmaiya N, L A, Sethi S. A retrospective cohort study on the potential link between dolutegravir-based anti-retroviral therapy and weight gain compared to efavirenz-based anti-retroviral therapy in a tertiary care center in Jabalpur, Madhya Pradesh. Natl J Physiol Pharm Pharmacol. (2024), [cited November 02, 2024]; 14(7): 1454-1458. doi:10.5455/njppp.2024.14.05215202429052024

Harvard Style

Anil, A. C., Gedam, . S., Sethi, . G., Parashar, . N., Barmaiya, . N., L, . A. & Sethi, . S. (2024) A retrospective cohort study on the potential link between dolutegravir-based anti-retroviral therapy and weight gain compared to efavirenz-based anti-retroviral therapy in a tertiary care center in Jabalpur, Madhya Pradesh. Natl J Physiol Pharm Pharmacol, 14 (7), 1454-1458. doi:10.5455/njppp.2024.14.05215202429052024

Turabian Style

Anil, Amal C, Sanjay Gedam, Gargi Sethi, Namita Parashar, Namita Barmaiya, Aryasree L, and Shivank Sethi. 2024. A retrospective cohort study on the potential link between dolutegravir-based anti-retroviral therapy and weight gain compared to efavirenz-based anti-retroviral therapy in a tertiary care center in Jabalpur, Madhya Pradesh. National Journal of Physiology, Pharmacy and Pharmacology, 14 (7), 1454-1458. doi:10.5455/njppp.2024.14.05215202429052024

Chicago Style

Anil, Amal C, Sanjay Gedam, Gargi Sethi, Namita Parashar, Namita Barmaiya, Aryasree L, and Shivank Sethi. "A retrospective cohort study on the potential link between dolutegravir-based anti-retroviral therapy and weight gain compared to efavirenz-based anti-retroviral therapy in a tertiary care center in Jabalpur, Madhya Pradesh." National Journal of Physiology, Pharmacy and Pharmacology 14 (2024), 1454-1458. doi:10.5455/njppp.2024.14.05215202429052024

MLA (The Modern Language Association) Style

Anil, Amal C, Sanjay Gedam, Gargi Sethi, Namita Parashar, Namita Barmaiya, Aryasree L, and Shivank Sethi. "A retrospective cohort study on the potential link between dolutegravir-based anti-retroviral therapy and weight gain compared to efavirenz-based anti-retroviral therapy in a tertiary care center in Jabalpur, Madhya Pradesh." National Journal of Physiology, Pharmacy and Pharmacology 14.7 (2024), 1454-1458. Print. doi:10.5455/njppp.2024.14.05215202429052024

APA (American Psychological Association) Style

Anil, A. C., Gedam, . S., Sethi, . G., Parashar, . N., Barmaiya, . N., L, . A. & Sethi, . S. (2024) A retrospective cohort study on the potential link between dolutegravir-based anti-retroviral therapy and weight gain compared to efavirenz-based anti-retroviral therapy in a tertiary care center in Jabalpur, Madhya Pradesh. National Journal of Physiology, Pharmacy and Pharmacology, 14 (7), 1454-1458. doi:10.5455/njppp.2024.14.05215202429052024

Author Login Reviewer Login About Publisher Editorial Policies Editorial Review Policy Peer Review Policy Editorial & Peer Review Process Publication Ethics and Publication Malpractice Statement Conflict of Interest Policy Plagiarism Policy Protection of Research Participants (Statement On Human And Animal Rights)Corrections, Retractions & Expressions of Concern Self-Archiving Policies Digital Archiving & Preservation Policies Statement of Informed Consent Advertising Policy Terms of Use License Information Copyright Information

About National Journal of Physiology, Pharmacy and Pharmacology

Contact Information

How to cite this article